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Abstract
Genome-wide screenings for copy number variations (CNVs) in patients with schizophrenia have demonstrated the
presence of several CNVs that increase the risk of developing the disease and a growing number of large rare CNVs; the
contribution of these rare CNVs to schizophrenia remains unknown. Using Affymetrix 6.0 arrays, we undertook a systematic
search for CNVs in 172 patients with schizophrenia and 160 healthy controls, all of Italian origin, with the aim of confirming
previously identified loci and identifying novel schizophrenia susceptibility genes. We found five patients with a CNV
occurring in one of the regions most convincingly implicated as risk factors for schizophrenia: NRXN1 and the 16p13.1
regions were found to be deleted in single patients and 15q11.2 in 2 patients, whereas the 15q13.3 region was duplicated in
one patient. Furthermore, we found three distinct patients with CNVs in 2q12.2, 3q29 and 17p12 loci, respectively. These
loci were previously reported to be deleted or duplicated in patients with schizophrenia but were never formally associated
with the disease. We found 5 large CNVs (.900 kb) in 4q32, 5q14.3, 8q23.3, 11q25 and 17q12 in five different patients that
could include some new candidate schizophrenia susceptibility genes. In conclusion, the identification of previously
reported CNVs and of new, rare, large CNVs further supports a model of schizophrenia that includes the effect of multiple,
rare, highly penetrant variants.
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Introduction
In recent years, the availability of high throughput technologies
investigating the genome at a resolution intermediate between that
of cytogenetic analysis (.2–5 Mb) and DNA sequencing (1–
700 bp) led to the demonstration that a large number of genomic
sequences, many of which encompass entire genes, vary in copy
number among individuals. These intermediate size deletions and
duplications, referred to as copy number variations (CNVs), are
more common in the general population than ever imagined
before and could account for more genomic differences among
sindividuals than single nucleotide polymorphisms (SNPs) [1,2].
Recent microarray studies also identified many CNVs in a variety
of complex mental disorders such as mental retardation [3,4],
autism spectrum disorders [5–8], and schizophrenia [9,10].
Regarding schizophrenia, genome-wide screening for CNVs has
demonstrated that deletions and duplications that disrupt genes
are more common in patients than in healthy subjects [11,12].
The pathogenicity of these CNVs seems to be correlated with their
size, because patient–control differences have involved mainly
large copy number variants [11,13,14]. Some of the large CNVs
were observed in several patients with schizophrenia [11,13–20];
others were described in only one or very few patients [12–
14,16,21]. In the case of the rare, large CNVs, however, their
contribution to the disorder cannot be ruled out. The observation
that deletions greater than 2 Mb occur extremely rarely, less than
0.04%, in healthy, cognitively unimpaired individuals seems
indeed to justify the inference that their presence, even in a single
individual, could have a high prior probability of being associated
with disease [14]. Furthermore, some of these CNVs were found
to be associated with a broad range of neuropsychiatric
phenotypes crossing the traditional boundaries of diagnosis [9].
Thus, these studies point strongly to a model of schizophrenia
pathogenesis that includes the effects of many different structural
variants. However, the fact that the CNVs identified so far
occurred at a combined frequency of only 2–3%, leaves still
undiscovered the vast majority of information on susceptibility to
schizophrenia [9].
In order to search for novel schizophrenia susceptibility genes
and/or loci for those reported in previous studies, and integrate
the databases of the CNVs putatively related to schizophrenia
susceptibility, we undertook a further systematic search for CNVs
in patients with schizophrenia and healthy controls, both of Italian
origin.
Results
Overall CNVs
Of the 180 patients with schizophrenia and 171 healthy controls
who were analyzed with the Affymetrix 6.0 microarrays, 172 cases
and 160 controls survived the filtering for quality control and
population stratification. A total of 4193 autosomal CNVs larger
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lower than 10 kb, were identified; 2189 were among the patients
and 2004 were in the control group (Table 1). The list of these
CNVs is available as a supporting file (File S1) uploadable in the
UCSC Genome Browser, (http://genome.ucsc.edu/).
The overall CNV rate per person was not statistically different
(t-test, p=0.31) between patients (12.763.7 SD) and controls
(12.563.7 SD). The deletion/duplication ratio was similar in the 2
sample populations (cases, 0.54; controls, 0.49; x
2, p=0.09)
(Table 1).
The median dimension of the CNVs was 204 and 209 kb for the
patients and controls, respectively. The largest CNV, 2566 kb, was
found in a patient; the largest CNV among the controls was
1837 kb.
Rare CNVs
Among the 4193 CNVs found, 179 can be considered rare.
Among the 179 CNVs, 85 were found in the controls (CNV/
person=0.5360.84) and 94 in the patients (CNV/per-
son=0.5560.83). The deletions (N=70) occurred at a modest,
but significantly higher frequency (x
2, p=0.026) in patients
(46.8%) compared with controls (30.6%). This is because the
deletion/duplication ratio significantly increased in patients when
only rare CNVs were considered (from 0.54 to 0.88; x
2, p=0.022).
This was not the case for controls (from 0.49 to 0.44; x
2,
p=0.679).
Most of the rare CNVs described in patients occurred as
singletons and only 12 were observed in more than one case; of
these 12 CNVs, 10 involved both patients and controls and the
remaining 2 were found in more than one patient but never in
controls. These 2 rare CNVs common to patients were a
duplication mapping at 3q21.2 (126.9–127.1 Mb) not encompass-
ing any gene, and a deletion mapping at 10q23.33 (96.4–96.5 Mb)
completely deleting a copy of the CYP2C18 gene and part of one
predicted isoform of the flanking gene, CYP2C19.
Regarding the size, rare CNVs larger than 900 kb did not occur
in the control group but were observed in 6 patients (Figure 1). All
these CNVs encompassed at least one gene and the deletion/
duplication ratio was 5:1 in favour of the deletions. The list of
these large CNVs is reported in Table 2 together with the
overlapping loci previously implicated in schizophrenia. The
duplication on chromosome 17 has been reported previously in a
healthy control [13], but the deletions on chromosomes 2, 4, 5, 8
and 11 are reported for the first time.
Identification of CNVs already reported to be associated
with schizophrenia
In relation to the CNVs most convincingly implicated in the risk
for schizophrenia [9,10,22], we found a patient with a deletion of
328 kb erasing the 59UTR and the first 3 exons of the NRXN1
gene (NM_004801.4) and two patients with a deletion in the
15q11.2 region. Moreover duplications at 15q13.3 and at
16p13.11 were found in single patients (Table 2). None of these
CNVs were found in controls. No patient presented CNVs at the
1q21, 16p11.2 and 22q11.1 loci. For CNVs previously described
only in patients with schizophrenia [11–14] but with limited
evidence of association with the disorder, deletions in 2q12.2
(106.2–107.9 Mb), 3q29 (197.2–198.8 Mb) and 17p12 (14.0–
15.4 Mb) were found in single patients (Table 2).
Discussion
This CNV analysis adds further weight to recent proposals that
high penetrant deletions may account, especially when rare, for a
portion of genetic susceptibility to schizophrenia [11,13,14], but
does not confirm previous reports [11,12] that people with
schizophrenia have a generalized increase in all the CNVs
combined. The study also contributes to the growing list of
specific CNVs potentially implicated in schizophrenia. Among the
CNVs more typically associated with schizophrenia, those located
in the NRXN1 gene and at the 15q11.2, 15q13.3 and 16p13.11 loci
collectively were found in 3% of our sample, a figure close to
prevalence rates already reported [9]. The 15q11.2 deletion was
found only in two patients (1%); this is in agreement with the
Table 1. Distribution of CNVs in patients and controls
a.
No. of
Subjects No. of CNVs CNVs/person
t-test
p-value
No. of
Deletions
No. of
Duplications
Deletions/
Duplications x
2 p-value
Controls 160 2004 12.563.7 0.31 656 1348 0.49 0.09
Patients 172 2189 12.763.7 771 1418 0.54
Total 332 4193 — — 1427 2766 — —
aOnly autosomal CNVs greater than 100 kb, called by at least 25 probes with an average distance between markers of less than 10 kb have been considered.
doi:10.1371/journal.pone.0013422.t001
Figure 1. Scatter plot of rare CNV size. Scatter plot of the
distribution of rare CNVs as a function of their dimension in controls
and patients. CNVs larger than 900 kb are circled in red.
doi:10.1371/journal.pone.0013422.g001
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(0.55–0.85%) [11,13,19].
Deletions in the region of the 15q13.3 locus are generally
considered pathogenic and have been found to be associated with
a broad spectrum of phenotypes ranging from schizophrenia to
mental retardation and autism [9]; the reciprocal duplications,
although less frequent, have already been observed at higher
frequency in patients with schizophrenia [11,13,14]. This also
suggests that the 15q13.3 duplication may be a risk factor for
schizophrenia [9,14].
Among CNV candidates for an association with schizophrenia
but not yet replicated, the current genome-wide screening study
has found 3 deletions. One is a large deletion at 17p12 that
overlapped the copy number state region found associated with
schizophrenia by Kirov et al. [13] and involving the peripheral myelin
protein 22 gene (PMP22). The second is a deletion in 3q29 that
overlapped the CNV observed initially by Walsh et al. [12] in 1 of
150 patients with schizophrenia and subsequently by the
International Schizophrenia Consortium (ISC) in 2 of 3391 cases
[11] (Figure 2). Combining previous and current data, it follows
therefore that the 3q29 deletion has so far been observed in 0.1%
of patients (4 out of 3719) but not in 3609 healthy controls. The
3q29 deleted region included at least 20 genes and, among these,
the most promising seems to be the Discs Large homolog 1 (DLG1)
which encodes for the presynaptic protein SAP97. Furthermore,
and more specifically, a recent study [23] has found an association
between some SNPs inside the DLG1 gene and males with
schizophrenia. The third CNV is a deletion at the 2q12.2 region
that erases 4 genes. This deletion has been reported for the first
time in this study, but duplications of the same region have already
been reported [13,14] in single patients with schizophrenia and
have been observed in one of our healthy control (Figure 3). So far,
CNVs in 2q12 have been reported to occur almost 10 times more
frequently (0.18% vs 0.02%) in people with schizophrenia (3 of
1656 cases) than in healthy controls (1 of 4036 individuals).
Prevalence rates on CNVs at 2q12.2 therefore suggest that it could
represent a schizophrenia susceptibility risk factor, but further data
are required before concluding that this region has a role in
schizophrenia pathogenesis.
The present study also suggests a possible involvement in
schizophrenia of new genes or loci inside large (.900 kb) regions
deleted only in patients. This is in agreement with proposals of
previous studies [13,14] that very large CNVs might have a high
prior probability of being associated with schizophrenia pheno-
types when observed almost exclusively in patients with schizo-
phrenia. One of the new deleted genes identified, follistatin-like 5
(FSTL5) located in the 4q32.1–32.2 region, encodes for the
follistatin-related protein 5 precursor, an extracellular protein
mainly expressed in B lymphoblasts, cerebellum and cerebellum
peduncles, and possibly involved [24] in the early development of
chemoattraction events responsible for the projection of the axons
of the dorsal root ganglion neurons toward the dorsal spinal cord.
A further new deletion, at 5q14.3, involved the EGF-like repeats and
Discoidin I-Like domains 3 (EDIL3) gene, which encodes an integrin-
ligand promoting adhesion of endothelial cells, inhibits formation
of vascular-like structures and might be involved in regulation of
vascular morphogenesis of remodelling during embryonic devel-
opment [25].
However, the CUB and Sushi multiple domains 3 (CSMD3) and beta-
1,3-glucuronyltransferase 1 (B3GAT1) genes located in the 8q23.3 and
11q25 regions, respectively, probably constitute the 2 new, most
promising deleted genes. CSMD3 is one of the 3 members of the
CSMD gene family that encodes for proteins with CUB and sushi
multiple domains. The CSMD3 gene is weakly expressed in most
tissues except the adult and fetal brain [26,27]. A recent study [28]
proposed CSMD3 as a candidate gene for autistic spectrum
disorders, because it maps in a break point region common to 2
unrelated autistic patients carrying balanced chromosome translo-
Table 2. List of all relevant CNVs found in our samples.
State Chr Cytoband Start
a End
Size
(kb)
Loss/
Gain
No. Of
Markers Genes
Case 2 p16.3 50,952,424 51,280,162 328 Loss 229 NRXN1
Case 2 q12.2–q12.3 106,232,909 107,873,857 1641 Loss 1013 PLGLA, RGPD3, ST6GAL2, RGPD4
Case 3 q29 197,185,549 198,838,373 1653 Loss 829 TFRC, ZDHHC19, OSTalpha, PCYT1A, TCTEX1D2, TM4SF19, UBXN7,
RNF168, C3orf43, WDR53, FBXO45, LRRC33, C3orf34, PIGX, PAK2,
SENP5, NCBP2, LOC152217, PIGZ, MFI2, DLG1, BDH1, LOC220729
Case 4 q32.1–q32.2 160,885,459 163,187,767 2302 Loss 1583 FSTL5
Case 5 q14.3 83,318,004 84,407,494 1089 Loss 593 EDIL3
Case 8 q23.3 112,965,276 115,531,385 2566 Loss 1417 CSMD3
Case 11 q25 133,461,668 134,449,982 988 Loss 749 JAM3, NCAPD3, VPS26B, THYN1, ACAD8, GLB1L3, GLB1L2, B3GAT1
Case 15 q11.2 18,700,540 20,968,714 2268 Loss 629 GOLGA6L6, GOLGA8C, BCL8, LOC646214, CXADRP2, POTEB, NF1P1,
LOC727924, OR4M2, OR4N4, OR4N3P, GOLGA8DP, GOLGA6L1,
TUBGCP5, CYFIP1, NIPA2, NIPA1, WHAMML1, GOLGA9P, HERC2P2
Case 15 q11.2 20,224,752 20,777,909 553 Loss 284 GOLGA6L1, TUBGCP5, CYFIP1, NIPA2, NIPA1, WHAMML1
Case 15 q13.2-q13.3 28,280,641 30,702,885 2422 Gain 1160 DKFZP434L187, CHRFAM7A, FAM7A1, FAM7A2, ARHGAP11B,
MTMR15, MTMR10, TRPM1, MIR211, KLF13, OTUD7A, CHRNA7,
FAM7A1, FAM7A2, ARHGAP11A
Case 16 p13.11 15,435,743 16,189,809 754 Gain 494 C16orf45, KIAA0430, NDE1, MIR484, MYH11, C16orf63, ABCC1, ABCC6
Case 17 p12 14,039,002 15,414,023 1375 Loss 1109 COX10, CDRT15, HS3ST3B1, MGC12916, CDRT7, PMP22, TEKT3,
CDRT4, FAM18B2
Case 17 q12 28,983,508 29,962,135 979 Gain 933 ACCN1, CCL genes, MCP3, TMEM132E
aGenome coordinates refer to the NCBI36/hg18 assembly.
doi:10.1371/journal.pone.0013422.t002
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addition, CSMD3 maps in a locus found to be linked to benign adult
familial myoclonic epilepsy [27]. These data suggest that CSMD3
could be a potential susceptibility candidate gene not only for
schizophrenia, but for a broader range of neuropsychiatric
disorders. B3GAT1, a member of the glucuronyltransferase gene
family, encodes for a protein that is the key enzyme during the
biosynthesis of the carbohydrate epitope HNK-1, present on a
number of cell adhesion molecules important for neurodevelop-
ment. Knockout mice for the B3GAT1 orthologous gene exhibit
impaired synaptic plasticity and spatial learning [29], 2 abnormal-
ities also described in patients with schizophrenia [30]. Further-
more, Jeffries and colleagues [31] described a family with the
chromosome translocation t(6;11)(q14.2;q25) segregating with
schizophrenia-like phenotype; because the breakpoint of chromo-
some 11 is close to the B3GAT1 gene, it has been hypothesized [31]
that polymorphic or other variations of the 11q telomere might
affect the activity of B3GAT1, thus becoming a risk factor for
schizophrenia and related psychoses.
In summary, the identification of new, rare, large CNVs
spanning potential candidate schizophrenia susceptibility genes, as
well as the CNVs previously reported to be associated with
schizophrenia, supports once again a model of schizophrenia that
includes among its causes the effect of many, rare, highly
penetrant structural variants. However, the limited number of
patients (,10%) with a potential pathologic CNV suggests that
these structural variations, even if they constitute a risk factor for
schizophrenia phenotype, are not the only risk factor.
Materials and Methods
Subjects
The study involved 351 subjects, 180 patients with schizophre-
nia and 171 healthy controls.
In agreement with our other recent reports [32,33], to be
eligible, both patients and controls had to be white and of Italian
descent for at least 2 generations, have no relatives among other
prospective participants, have given written informed consent,
Figure 2. CNVs at 3q29. UCSC Genome Browser image of the 3q29 region found deleted in a patient with schizophrenia from this study and in
three patients from previous studies [11,12].
doi:10.1371/journal.pone.0013422.g002
Figure 3. CNVs at 2q12. UCSC Genome Browser image of the 2q12 region found deleted in a patient and duplicated in a control in our study. The
same region was previously reported as duplicated in two other patients with schizophrenia [13,14]. Deletions and duplications are shown in red and
blue, respectively.
doi:10.1371/journal.pone.0013422.g003
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criteria.
Patients had to satisfy the DSM-IV-TR criteria [34] for
schizophrenia in the absence, during their lifespan, of co-
morbidities with other DSM-IV-TR Axis I disorders, with the
exception of nicotine and caffeine abuse.
The controls had to have no lifetime personal evidence of any
DSM-IV-TR Axis I disorder, again with the exception of nicotine
and caffeine abuse, and to present a negative family history for
psychoses and mood disorders in their first-degree relatives.
The diagnosis of schizophrenia was made following a detailed
clinical interview, complemented by a revision of all medical
records and, when required, a DSM-IV-TR adjusted version of
the Standardized Clinical Interview for DSM-IV Axis I Disorders,
Clinician Version [35]. The healthy controls were initially asked
about previous specialist examinations and consumption of
psychopharmacological agents exceeding a sporadic use of
benzodiazepines and hypnotics for tension and/or insomnia.
Prospective controls who gave negative answers to these 2
questions also underwent detailed clinical interviews complement-
ed, if necessary, by a DSM-IV-TR adjusted version of the
Diagnostic Interview for Genetic Studies [36].To exclude a family
history for psychoses and mood disorders in healthy controls, they
and, in case of doubt, a family member, were interviewed
following an ad hoc questionnaire.
A team of psychiatrists with a common experience working on
patients with schizophrenia was in charge of clinical assessments
and decisions about eligibility for the study, after dedicated
training on the procedures and demonstration of valid inter-rater
reliability. Two physicians in the team independently evaluated
each prospective participant. In cases of discordance, a joint
revision of all the material took place in the presence of an
independent referee who made the final decision after discussion.
The patients were enrolled from those admitted to facilities of
the Brescia University and Spedali Civili Psychiatric Unit and the
Brescia IRCSS Fatebenefratelli. The controls consisted of doctors,
nurses, employers and attendants working in the 2 hospitals,
students of Brescia University, or their relatives.
The format of the written informed consent was approved by a
local Ethic Committee (CEIOC) (act number 3/2004 of 01/22/
2004). The consent form provided a concise but unequivocal
explanation about the aims of the study and an explicit guarantee
of anonymity and the impossibility of identification details as a
unique number linked all the individual data.
Genotyping
All samples were genotyped by Affymetrix Human Mapping
GeneChip 6.0 arrays with a total of 2 millions of probes, half of
which were polymorphic. DNA was processed according to the
instructions provided in the Affymetrix Genome-Wide Human
SNP Nsp/Sty 6.0 Assay Manual. Initial analysis of the array to
obtain intensity data was performed using Affymetrix GeneChip
Command Console Software (AGCC). The AGCC probe cell
intensity data were then analyzed with GenotypeConsole 3.01
(GTC3.01) to obtain genotype data. Quality thresholds were used
to reduce the number of genotype errors. According to Affymetrix
specifications, samples that had a QC#0.4 were discarded from
further analyses. After this quality step, 3 samples were excluded
from population structure analysis and from copy number state
analysis.
Quality controls of population structure
The chp.files generated by the Birdseed v2 algorithm imple-
mented in GTC 3.01 were imported into the HelixTree 7.0.3
software for statistical analyses (Golden Helix SVS, Bozeman,
MT, USA). Before performing any type of analysis, cleaning of the
data was performed. In particular, from the initial 906,599 SNPs,
we excluded from the analysis those SNPs on the sex chromo-
somes, those with a call rate ,95%, a minor allele frequency ,0.1
and those with Hardy–Weinberg disequilibrium p-values ,1610
–
7. After these steps, 560,044 SNPs were retained for population
stratification analysis.
Population stratification, which can be responsible for spurious
associations, was controlled by means of an enhanced version of
EIGENTRAT present in HelixTree 7.0.3. Using this approach,
we identified 26 outlier samples. The analysis of these samples with
GenotypeColour
TM [37] revealed the presence of cryptic related-
ness among the samples. After taking the relatedness into account,
13 samples were discarded from further analysis. The re-analysis
of the data after the elimination of related samples colocated the
previous outlier samples with all the others, confirming that cryptic
relatedness and not other types of stratification was the cause of
their previous marginal position.
Generation of CNVs calls
All subjects who passed the QC threshold and population
stratification procedures were used for copy number (CN) state
analysis. The CN state calls were generated from the BRLMM-P-
Plus algorithm implemented in GTC 3.0.1. This algorithm
compared the intensity signal of each marker in each sample
against a reference pool formed from a group of 270 samples
derived from the HapMap database. After this comparison, the
software generates a median intensity value for each marker, and
the value obtained is reported as the log2 ratio or CN state.
According to Affymetrix protocols, samples with a median
absolute pairwise difference (MAPD) $0.4 were discarded from
further analyses. After this quality control step, 3 samples were
eliminated. The copy number state information of the final sample
of 332 subjects (172 patients with schizophrenia and 160 healthy
controls) was then used by the Affymetrix segmentation algorithm
to identify CNVs. To reduce the presence of false-positive CNVs,
the segmentation algorithm parameters were set to consider as a
CNV only those regions larger than 100 kb, comprised of at least
25 contiguous markers without diploid state and with an average
probe density lower than 10 kb. The segmentation algorithm
was also used to extrapolate from all the CNVs identified only
those with at least 50% overlap with CNV regions previously
reported by other authors in patients with schizophrenia
[12–14,16,17,19–21].
Statistical analysis on CNV calls
The t-test was used to evaluate patient–control differences in the
average number of CNVs per sample, whereas the x
2-test was
used to compare the frequency distribution of deletions and
duplications in the 2 populations. The one-tailed was used to test if
CNVs stratified by size or type (duplication or deletion) were
significantly associated with schizophrenia.
Analysis of rare CNVs
To verify the presence of rare, relatively highly penetrant CNVs
that could be responsible for a proportion of the schizophrenia
phenotype, we defined as rare those CNVs with a #80%
overlapping segment with a CNV previously described in the
DGV (release 18v6; http://projects.tcag.ca/variation/). The
choice of this threshold is arbitrary, but substantially the same
results were obtained if only those CNVs with 0% overlap were
retained or only those with 100% overlap were discarded (data not
shown).
CNVs in Schizophrenia
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Validation of CNVs larger than 900 kb was performed by real-
time polymerase chain reaction technology. Applied Biosystems
TaqManH Copy Number Assays Hs06710043_cn, Hs06722515_cn,
Hs05233869_cn, Hs00492735_cn were used to validate CNVs inside
the region 4q32.1-32.2, 5q14.3, 11q25 and 17q12, respectively.
Custom TaqManH Copy Number Assays ST6GAL2_cn_1 and
CSMD3_cn_1 were used to validate CNVs inside the 2q12.2-q12.3
and 8q23.3 regions, respectively. Assays were performed in
quadruplicate in 96-well plates with 5 ng of DNA per reaction (for
the custom assays,10 ng were used). Copy numbers were determined
using CopyCaller software v.1.0 (Applied Biosystems).
Note Added in Proof
While this paper was under review, Mulle et al. (Am. J. Hum.
Genet 87, 229–236) reported that ‘‘Microdeletions of 3q29 Confer
High Risk for Schizophrenia’’. These data confirm our hypothesis
of the relevance of deletions in this region in schizophrenia
pathogenesis.
Supporting Information
File S1 The list of CNVs identified in this study. A total of 4193
autosomal CNVs larger than 100 kb, called by at least 25 probes
with an average distance lower than 10 kb.
Found at: doi:10.1371/journal.pone.0013422.s001 (0.13 MB
TXT)
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